Survival Analysis Assistant

Survival Analysis Assistant – HCP Decision Helper

Survival Analysis Assistant

Quick helper for HCPs to interpret hazard ratios, Kaplan–Meier results, and time-to-event endpoints, and to think through whether a treatment effect is statistically and clinically meaningful.

1. Enter Trial & Patient Context

Fill what you know. Leave anything blank if not reported.

Outcome & Direction
Baseline Risk & Time Horizon
Side Effects, Cost & Patient Priorities
Free-Text Notes (optional)

This tool is for education and decision support only. It does not replace clinical judgment, guidelines, or patient preferences.

2. Interpretation & Decision Support

The assistant summarizes the statistical signal, absolute effect, and how to frame this for patients.

Statistical Signal & Uncertainty Awaiting input
Enter HR and (optionally) confidence interval / p-value, then click “Analyze survival data.”
Absolute Effect & “Out of 100 Patients”
If you provide a baseline risk (%), this section will estimate treated risk, absolute difference, and a rough NNT/NNH.
Clinical Framing for the HCP
This will provide a short narrative you can adapt when discussing options with patients or colleagues.
Decision Support Summary
This section synthesizes the signal, absolute benefit, side effects, cost, and patient priorities into a simple “lean toward / cautious / avoid” suggestion.

Tip: Use this as a teaching tool with learners. Ask them for their interpretation first, then compare with the assistant’s suggestions and critique both.

3. Solved Example Cases

Click “Load this example” to auto-fill the form and see how the assistant interprets each real-world scenario.

Example 1 – Heart Failure Drug (Benefit)

Endpoint: death or HF hospitalization (bad outcome). HR 0.80 (95% CI 0.70–0.92, p=0.004). Baseline risk 40% over 2 years. Moderate toxicity and cost. Patient wants to maximize survival.

Teaching point: Significant reduction in bad outcomes with moderate trade-offs – usually supports offering the drug, especially in higher-risk patients.

Example 2 – DFU Hydrogel Dressing (Faster Healing)

Endpoint: complete healing (good outcome). HR 1.90 (95% CI 1.30–2.70, p=0.01). Baseline healing 50% by 12 weeks. Low toxicity, moderate cost. Balanced patient priorities.

Teaching point: Large increase in healing over time with minimal downside – a good candidate for step-up therapy in stalled or higher-risk ulcers.

Example 3 – Oncology Maintenance (No Clear Benefit)

Endpoint: overall survival (bad outcome). HR 0.95 (95% CI 0.88–1.03, p=0.20). Baseline mortality 30% over 3 years. High fatigue and high cost. Patient prioritizes quality of life.

Teaching point: No clear survival signal with high toxicity and cost – typically argues against routine use; consider only in special circumstances.

Example 4 – AF & Alcohol Reduction (Lifestyle Intervention)

Endpoint: AF recurrence (bad outcome). HR 0.55 (95% CI 0.36–0.84, p=0.01). Baseline recurrence 50% over 6 months. Very low toxicity and cost. Patient wants fewer episodes and better QoL.

Teaching point: Strong survival-style signal in favor of a lifestyle change with almost no downside – high-value intervention for counseling and shared decision making.